

This document is intended to provide health care providers with approaches for individuals who have received COVID-19 vaccination outside of Canada. The WHO list of EUA qualified COVID-19 vaccines will be updated over time as additional COVID-19 vaccines receive emergency use listing, and as such, this document will be updated accordingly. More information on COVID-19 vaccines listed for emergency use can be found on the [WHO website](#), under the tab “Status of COVID-19 vaccines within WHO EUL/PQ evaluation process.”

Manufacturer	Name of Vaccine	Type of vaccine <sup>1</sup>	WHO EUA qualified	Approved schedule <sup>2, 3</sup>	Second dose options for completion of series in BC <sup>4</sup>
Pfizer-BioNTech	BNT162b2 / COMIRNATY / Tozinameran (INN)	mRNA	✓	Two doses, 21-28 days apart	- Moderna - Pfizer-BioNTech
Moderna	mRNA-1273	mRNA	✓	Two doses, 28 days apart	- Moderna - Pfizer-BioNTech
AstraZeneca	AZD1222 Vaxzevria	Adenovirus (CHAdOx1) vector	✓	Two doses, 4-12 weeks apart	- AstraZeneca - COVISHIELD - Moderna - Pfizer-BioNTech
Serum Institute of India	COVISHIELD	Adenovirus (CHAdOx1) vector	✓	Two doses, 4-12 weeks apart	- AstraZeneca - COVISHIELD - Moderna - Pfizer-BioNTech
Janssen (Johnson & Johnson)	Ad26.COV2.5	Adenovirus type 26 vector	✓	One dose	N/A – one dose series
SinoPharm / Beijing Institute of Biological Products (BIBP)	Covilo / BBIBP-CorV	Whole inactivated Coronavirus	✓	Two doses, 21-28 days apart	- Moderna - Pfizer-BioNTech
Sinovac	CoronaVac	Whole inactivated Coronavirus	✓	Two doses, 14-28 days apart	- Moderna - Pfizer-BioNTech
Bharat Biotech, India	COVAXIN	Whole inactivated Coronavirus	✓	Two doses, 28 days apart	- Moderna - Pfizer-BioNTech
The Gamaleya National Center	Sputnik V	Human adenovirus vector	pending		
SinoPharm / Wuhan Institute of Biological Products (WIBP)	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	Whole inactivated Coronavirus	pending		
CanSinoBio	Ad5-nCoV	Adenovirus Type 5 vector	pending		
Novavax	NVX-CoV2373 / Covovax	Protein subunit	pending		
CureVac	CVnCoV/CV07050101 Zorecimeran (INN)	mRNA	pending		

---

<sup>1</sup> Types of vaccine are:

- mRNA: Pfizer, Moderna
- Adenovirus (ChAdOx) vector: AstraZeneca, COVISHIELD \*
- Whole inactivated Coronavirus: Sinopharm, Sinovac, Covaxin
- Protein subunit: Novavax

\* The other adenovirus-based vaccines (i.e., Janssen, Sputnik, CanSinoBio) use different vectors and so are not immunologically the same as either the AstraZeneca or COVISHIELD adenovirus vector vaccines.

<sup>2</sup> Individuals who have received a complete series with a vaccine that is WHO EUA qualified are considered fully vaccinated and no further doses are required. However, one additional dose of a COVID-19 mRNA vaccine should be provided for individuals upon request if they have been vaccinated with a WHO-approved vaccine series that is not authorized in Canada. The minimum interval between the preceding dose and the additional dose is 4 weeks.

<sup>3</sup> Individuals who have received a series with a vaccine that is not WHO EUA qualified should be offered a full COVID-19 vaccine series using a vaccine available in BC. There is no minimum interval required when restarting the series following receipt of a non-WHO approved vaccine.

<sup>4</sup> Individuals who have received a first dose of a COVID-19 vaccine overseas that is also available in BC should receive the same vaccine for their second dose if readily available, and if they meet the current BC eligibility criteria for 2<sup>nd</sup> dose (i.e., at least 4 weeks following first dose). If the vaccine they received for their first dose is not available in BC, but the **same type of vaccine** is available, this should be offered. A 6-8 week interval between doses is recommended. A minimum interval of 4 weeks is acceptable, if required.